Key result
Ventricular late potentials linked to ~13.6-fold higher mortality in PAH patients.
Why the study?
The prognostic significance and relevance of non-invasive electrocardiographic parameters in pulmonary arterial hypertension compared to left ventricular heart failure remained unclear.
Do non-invasive 24-hour ambulatory electrocardiographic parameters, such as ventricular late potentials, predict mortality in patients with pulmonary arterial hypertension?
Cohort (n=72)
Do non-invasive 24-hour ambulatory electrocardiographic parameters, such as ventricular late potentials, predict mortality in patients with pulmonary arterial hypertension?
Ventricular late potentials are present in 19% of pulmonary arterial hypertension patients and serve as a significant independent predictor of mortality.
Answers are grounded in this paper and cite their sources.
Ventricular late potentials may flag higher mortality risk in PAH; leaves open incremental value beyond established markers in larger cohorts.
BACKGROUND: Whether non-invasive electrocardiographic parameters may be of similar relevance in pulmonary arterial hy-pertension (PAH) as in left ventricular heart failure (LVHF) remains unclear. AIM: To examine a profile of electrocardiographic parameters in PAH and to determine their prognostic significance. Com-parison of profile in patients with pulmonary hypertension secondary to left ventricular dysfunction was planned in order to put PAH group results into context. METHODS: We included 41 patients with type 1.1/1.4.4 (according to the European Society of Cardiology) PAH and 31 patients with LVHF and type 2.1 pulmonary hypertension. All patients underwent 24-h ambulatory electrocardiography monitoring. RESULTS: Among heart rate variability parameters, only RMSSD was different (mean, 75 ms [PAH] vs. 112 ms [LVHF], p = 0.016). In PAH, fewer patients had ventricular tachycardia (15% vs. 48%, p = 0.004), abnormal deceleration capacity (54% vs. 84%, p = 0.011), positive heart rate turbulence (11% vs. 48%, p = 0.003), severe autonomic failure (10% vs. 39%, p = 0.005), and ventricular late potentials (LP) (19% vs. 62%, p = 0.001). In PAH, four deaths occurred in 42 months. In univariate analysis, the risk factors for death were: LP (hazard ratio 13.55, 95% confidence interval 1.41-130.72; p = 0.024), age, N-terminal prohormone of B-type natriuretic peptide, while the protective factors were minimal and mean heart rate, as well as the six-minute walk test (6MWT) distance. In multivariate analysis, the influence of LP and the 6MWT distance remained significant. CONCLUSIONS: Ventricular LP were present in 19% of PAH patients and were the most powerful risk factor of mortality .
No takes yet. Share an insight, caveat, or question.
Uznańska‐Loch et al. (2018) conducted a cohort in Pulmonary arterial hypertension (PAH) and left ventricular heart failure (LVHF) with secondary pulmonary hypertension (n=72). Ventricular late potentials (LP) on 24-h ambulatory electrocardiography vs. Absence of ventricular late potentials (and comparison between PAH and LVHF cohorts) was evaluated on Mortality (death) in PAH patients (HR 13.55, 95% CI 1.41-130.72, p=0.024). Ventricular late potentials were present in 19% of PAH patients and strongly predicted mortality over 42 months.
Synapse has enriched 10 related papers. Consider them for comparative context: